Labiotech.eu

News and Trends 4 Oct 2022

Absolute Biotech launches as unified antibody company

Absolute Biotech has launched as a unified company to join antibody-centric brands from around the world. Absolute Biotech specializes in antibody reagents and services, adding value to existing antibodies, reagents and kits through annotation, validation, sequencing, engineering and recombinant manufacturing. The combined company will leverage each brand’s antibody expertise to advance the creation and availability […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Spinoff Biohaven launches with $258M and “incredible pipeline”

Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric as […]

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines. Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Ginkgo Bioworks acquires Altar and Circularis

Ginkgo Bioworks has announced the acquisition of two biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening platform. Altar acquisition A fleet of Altar’s automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo’s Foundry to serve customers across food and […]

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

HumanFirst launches industry’s largest decentralized clinical trial database

HumanFirst has launched two new versions of the Atlas platform designed specifically for researchers in industry (AtlasPro) and academia (AtlasEDU). Atlas was created by HumanFirst to unlock better research for all humans sooner, and has been used for planning and deployment of trustworthy hybrid and at-home clinical trials by 22 of the 25 largest pharmaceutical […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review. The study, “Improving the Efficiency of […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. POLB 001 The USPTO granted a patent for the majority of Poolbeg’s claims around the […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Discovery of how metastatic cancer cells infiltrate the liver may lead to new drugs

Approximately 90% of cancer-related deaths are due to metastasis when cancer spreads and forms new tumors. The liver is considered the most vulnerable organ to metastatic cancer: the five-year survival rate after surgery to remove liver metastases is as low as 30 to 50%, so developing treatments to prevent liver metastasis is urgently needed. A […]

October 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Astellas and Pantherna to work together on mRNA-based medicine through direct reprogramming

Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation). Direct reprogramming is the direct conversion of the fate of cells without passing through the pluripotent state. This agreement expands the scope of the technology evaluation agreement for […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia

The Canadian government is providing more than C$11.1 million (US$8.1 million) for two new mRNA vaccine projects at the University of British Columbia (UBC). The funding, through the Pacific Economic Development Agency of Canada (PacifiCan), is for UBC to enhance the delivery and efficacy of mRNA vaccines. PacifiCan is investing the money through its Regional […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Oncopeptides starts European commercialization of myeloma drug in Germany

Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in Germany. It marks the first market in Europe where the drug is being launched. On August 18, the European Commission granted Pepaxti, in combination with dexamethasone, Marketing Authorization in the European Union and countries in the European Economic Area, for […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Absolute Biotech launches as unified antibody company

Spinoff Biohaven launches with $258M and “incredible pipeline”

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Ginkgo Bioworks acquires Altar and Circularis

HumanFirst launches industry’s largest decentralized clinical trial database

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

Discovery of how metastatic cancer cells infiltrate the liver may lead to new drugs

Astellas and Pantherna to work together on mRNA-based medicine through direct reprogramming

Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia

Oncopeptides starts European commercialization of myeloma drug in Germany

Estrella and TradeUP merge to become publicly traded company

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!